Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Alfuzosin Hydrochloride

FDA-approved product (tablet, extended release, oral), marketed as Alfuzosin Hydrochloride, Uroxatral.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Alfuzosin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Alfuzosin Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Alfuzosin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score

    NCT00540891 · start 2003-02

    Registered record
    Registry ID
    NCT00540891
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    ALFUZOSIN
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-02
    Completion
    2004-10
    Enrolment
    372

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionALFUZOSIN
    PhasePhase 3
    Registry statusCompleted

  • Clinical Trial in Males With BPH (Enlarged Prostate)

    NCT00029822 · start 2001-05

    Registered record
    Registry ID
    NCT00029822
    Conditions
    Urinary Retention; Prostatic Hyperplasia; Benign Prostatic Hypertrophy
    Interventions
    Alfuzosin (SL770499)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-05
    Completion
    2005-03
    Enrolment
    1,522

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Retention; Prostatic Hyperplasia; Benign Prostatic Hypertrophy
    InterventionAlfuzosin (SL770499)
    PhasePhase 3
    Registry statusCompleted

  • ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH

    NCT00290030 · start 2001-05

    Registered record
    Registry ID
    NCT00290030
    Conditions
    Prostatic Hyperplasia; Acute Urinary Retention
    Interventions
    Alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-05
    Completion
    2004-10
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia; Acute Urinary Retention
    InterventionAlfuzosin
    PhasePhase 3
    Registry statusCompleted

  • Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fasted Conditions

    NCT01418586

    Registered record
    Registry ID
    NCT01418586
    Conditions
    Healthy
    Interventions
    Torrent's Alfuzosin Extended Release Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTorrent's Alfuzosin Extended Release Tablet
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fed Conditions

    NCT01418599

    Registered record
    Registry ID
    NCT01418599
    Conditions
    Healthy
    Interventions
    Torrent's Alfuzosin Extended Release Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTorrent's Alfuzosin Extended Release Tablet
    PhasePhase 1
    Registry statusCompleted